What is Applied Proteomics?
Applied Proteomics, Inc. is a biotechnology firm specializing in the development and commercialization of protein-based diagnostic tests. Their flagship product, the SimpliPro Colon Test, is designed for healthcare providers to assess colorectal wellness by evaluating 11 protein markers associated with the risks of esophageal cancer and advanced adenoma. This innovative blood test aims to improve patient adherence to colonoscopy procedures by integrating into routine health examinations, offering a comprehensive risk assessment in a single report. The company's focus on early cancer detection and risk stratification underscores its commitment to advancing diagnostic capabilities within the healthcare industry.
How much funding has Applied Proteomics raised?
Applied Proteomics has raised a total of $54.5M across 3 funding rounds:
Series A
$4M
Series B
$22.5M
Series C
$28M
Series A (2007): $4M, investors not publicly disclosed
Series B (2012): $22.5M led by Vulcan Capital Management and Domain Associates
Series C (2013): $28M supported by Genting Berhad, Vulcan Capital Management, and Domain Associates
Key Investors in Applied Proteomics
Genting Berhad
Genting Berhad, a Malaysian conglomerate founded in 1965, is a diversified holding company with significant interests in hospitality and leisure. Its investment in Applied Proteomics suggests a strategic interest in diversifying its portfolio into the healthcare and biotechnology sectors.
Vulcan Capital Management
Vulcan Capital Management is a private equity firm based in New York that focuses on investments in energy and natural resources. Their participation in Applied Proteomics' funding rounds indicates a potential strategic alignment or a broader investment thesis that includes innovative healthcare technologies.
Domain Associates
Domain Associates is a venture capital firm established in 1985, with a strong specialization in the biotechnology and healthcare sectors. They have a proven track record of funding numerous biopharmaceutical, device, and diagnostic companies, leading to successful IPOs and M&A events.
What's next for Applied Proteomics?
With substantial enterprise-level backing, Applied Proteomics is poised to scale its operations and further develop its diagnostic platforms. The strategic investment suggests a focus on expanding market reach, enhancing product development, and potentially exploring new applications for its protein marker technology. Future endeavors will likely involve strengthening partnerships with healthcare providers and payers, as well as continuing research into novel biomarkers for disease detection. The company's established funding history, culminating in this recent significant capital infusion, signals a strong potential for continued innovation and market penetration in the competitive diagnostics landscape.
See full Applied Proteomics company page
